Conceptos Categóricos

Crónicas de autores

Pere-Joan Cardona *

Autor invitado por SIIC

En el trabajo se propone la utilización de una nueva vacuna para reducir el tiempo de tratamiento antibiótico de la infección tuberculosa latente

LA INMUNOTERAPIA CON RUTI REDUCE EL PERIODO DE TRATAMIENTO DE LA INFECCION TUBERCULOSA LATENTE

La RUTI es una vacuna generada a partir de fragmentos celulares de M. tuberculosis detoxificados que permiten generar una respuesta equilibrada de tipo Th1/Th2/Th3, ante un amplio abanico de antígenos, además de una intensa producción de anticuerpos. El tratamiento con RUTI, posterior a la quimioterapia, ya ha demostrado su eficacia en modelos experimentales en ratones y cobayos, sin generar ninguna respuesta tóxica.

*Pere-Joan Cardona
describe para SIIC los aspectos relevantes de su trabajo
INMUNOTHERAPY WITH FRAGMENTED MYCOBACTERIUM TUBERCULOSIS CELLS INCREASES THE EFFECTIVENESS OF CHEMOTHERAPY AGAINST A CHRONICAL INFECTION IN A MURINE MODEL OF TUBERCULOSIS
Vaccine,
23(11):1393-1398 Feb, 2005

Esta revista, clasificada por SIIC Data Bases, integra el acervo bibliográfico
de la Biblioteca Biomédica (BB) SIIC.

Institución principal de la investigación
*Fundació Institut per a la Investigació en Ciències de la Salut Germans Trias I Pujol, Badalona, España, Badalona, España
Imprimir nota
Referencias bibliográficas
1. World Health Organization. Global Tuberculosis Control. WHO Report 2001. Geneva, Switzerland, WHO/CDS/TB/2001.287.
2. Cunningham AF, Spreadbury CL. Mycobacterial stationary phase induced by low oxygen tension: cell wall thickening and localization of the 16-kilodalton alpha-crystallin homolog. J Bacteriol 1998; 180:801-8.
3. Michele TM, Ko C, Bishai WR. Exposure to antibiotics induces expression of the Mycobacterium tuberculosis sigF gene: implications for chemotherapy against mycobacterial persistors. Antimicrob Agents Chemother 1999; 43:218-25.
4. Andersen P, Askgaard D, Ljungqvist L, Bentzon MW, Heron I. T-cell proliferative response to antigens secreted by Mycobacterium tuberculosis. Infect Immun 1991; 59:1558-63.
5. Grosset J. Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1980; 1:231-41.
6. Moreira AL, Tsenova L, Aman MH, Bekker LG, Freeman S, Mangaliso B, et al. Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice. Infect Immun 2002; 70:2100-7.
7. Turner J, Rhoades ER, Keen M, Belisle JT, Frank AA, Orme IM. Effective preexposure tuberculosis vaccines fail to protect when they are given in an immunotherapeutic mode. Infect Immun 2000; 68:1706-9.
8. Cardona PJ, Gordillo S, Diaz J, Tapia G, Amat I, Pallares A, et al. Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun 2003; 71:5845-54.
9. Sonnenberg MG, Belisle JT. Definition of Mycobacterium tuberculosis culture filtrate proteins by two-dimensional polyacrylamide gel electrophoresis, N-terminal amino acid sequencing, and electrospray mass spectrometry. Infect Immun 1997; 65:4515-24.
10. Rabilloud T. Mechanisms of protein silver staining in polyacrylamide gels: a 10-year synthesis. Electrophoresis 1990; 11:785-94.
11. Medina E, North RJ. Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology 1998; 93:270-4.
12. Cobbold S, Waldmann H. Infectious tolerance. Curr Opin Immunol 1998; 10:518-24.
13. Lucas SB. Histopathology. In: Davies PDO, editor, Clinical Tuberculosis. London, Chapman & Hall, 1998: 113-27.
14. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123:445-68.
15. Orme I. The latent tuberculosis bacillus (I'll let you know if I ever meet one). Int J Tuberc Lung Dis 2001; 5:589-93.
16. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67:4531-8.
17. Cardona PJ, Julian E, Valles X, Gordillo S, Munoz M, Luquin M, et al. Production of antibodies against glycolipids from the Mycobacterium tuberculosis cell wall in aerosol murine models of tuberculosis. Scand J Immunol 2002; 55:639-45.
18. Swain SL, Croft M, Dubey C, Haynes L, Rogers P, Zhang X, et al. From naive to memory T cells. Immunol Rev 1996; 150:143-67.
19. Power CA, Wei G, Bretscher PA. Mycobacterial dose defines the Th1/Th2 nature of the immune response independently of whether immunization is administered by the intravenous, subcutaneous, or intradermal route. Infect Immun 1998; 66:5743-50.
20. Hernandez-Pando R, Pavon L, Arriaga K, Orozco H, Madrid-Marina V, Rook G. Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 1997; 65:3317-27.
21. Gruppo V, Orme IM. Dose of BCG does not influence the efficient generation of protective immunity in mice challenged with Mycobacterium tuberculosis. Tuberculosis (Edinb) 2002; 82:267-73.
22. Hernandez-Pando R, Orozco H, Arriaga K, Sampieri A, Larriva-Sahd J, Madrid-Marina V. Analysis of the local kinetics and localization of interleukin-1 alpha, tumour necrosis factor-alpha and transforming growth factor-beta, during the course of experimental pulmonary tuberculosis. Immunology 1997; 90:607-17.
23. Koch R. Weitere. Mitteilungen uber ein Heilmittel gegen Tuberku-lose. Dtsch. Med. Wochenschr. 1890; 16:1029–32.
24. Roach TIA, Barton CH, Chatterjee D, Blackwell JM. Macrophage activation: lipoarabinomannan from avirulent and virulent strains of Mycobacterium tuberculosis differentially induces the early genes c-fos, KC, JE and tumor necrosis factor-a. J Immunol 1993; 150: 1886-96.
25. Karplus TE, Ulevitch RJ, Wilson CB. A new method for reduction of endotoxin contamination from protein solutions. J Immunol Methods 1987; 105; 211-20.
26. Cardona PJ, Llatjos R, Gordillo S, Diaz J, Viñado B, Ariza A, et al. Towards a 'human-like' model of tuberculosis: intranasal inoculation of LPS induces intragranulomatous lung necrosis in mice infected aerogenically with Mycobacterium tuberculosis. Scand J Immunol 2001; 53:65-71.
27. Stumbles PA, McWilliam AS, Holt PG. Dendritic cells and mucosal macrophages. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J McGhee JR, editors. Mucosal Immunology. San Diego, Academic Press, 1999; 397-412.
28. Williams A, Reljic R, Naylor I, Clark SO, Falero-Diaz G, Singh M, et al. Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology 2004; 111:328-33.
Otros artículos de Pere-Joan Cardona

Cardona PJ, Cooper A, Orme I.M, Luquín M, Ariza A, Ausina V. The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model due to a more rapid induction of systemic immunity. Scand J Immunol 1999; 35:247-253.
Cardona PJ, Llatjós R, Gordillo S, Díaz J, Ojanguren I, Ariza A, Ausina V. Evolution of granulomas in mice infected aerogenically with Mycobacterium tuberculosis. Scan J Immunol 2000; 52:156-163.
Cardona PJ, Llatjós R, Gordillo S,Viñado B, Díaz J, Ariza A, Ausina V, Towards a “human-like” model of tuberculosis: Local inoculation of LPS in lungs of Mycobacterium tuberculosis aerogenically infected mice induces intragranulomatous necrosis. Scand J Immunol 2001; 53:65-71.
Cardona PJ, Julian E, Gordillo S, Díaz J, Vallès X, Luquín M, Ausina V. Production of antibodies against glycolipids from the cell wall of M. tuberculosis in a murine model of tuberculosis. Scand J Immunol. 2002; 55:639-645.
Cardona PJ, Gordillo S, Amat I, Pallarés A, Vilaplana C, Tapia G, Ariza A, Ausina V. Catalase-peroxidase activity has no influence on virulence in a murine model of tuberculosis. Tuberculosis. 2003; 83(6):351-359.
Cardona PJ, Gordillo S, Díaz J, Tapia G, Amat I, Pallarés A, Vilaplana C, Ariza A, Ausina V Widespread bronchogenic dissemination makes DBA/2 mice more susceptible than C57BL/6 mice to experimental aerosol infection with Mycobacterium tuberculosis. Infect Immun. 2003; 71(10):5845-5854.
Cardona PJ, Ruiz-Manzano J. On the Nature of Mycobacterium tuberculosis latent bacilli. Eur J Respir 2004; 24: 1044-51. 8. Cardona PJ. Lessons from the murine experimental model of tuberculosis: the need to reconsider some topics. Immunología 2004; 24-29.
Cardona PJ, Ausina V. Histopatología de la tuberculosis. Aproximación a la evolución de las lesiones pulmonares en modelos de experimentación animal inducidos mediante aerosol. Arch Bronconeumol 2000;36:645-50.
Cardona PJ, Ausina V. Hipersensibilidad retardada y necrosis caseosa en el granuloma tuberculoso. Nuevas ideas para el diseño de una nueva vacuna contra la tuberculosis humana. Med Clin (Bar) 2000;115:503-9.

Para comunicarse con Pere-Joan Cardona mencionar a SIIC como referencia:


Autor invitado
16 de mayo, 2005
Descripción aprobada
30 de julio, 2005
Reedición siicsalud
28 de octubre, 2019

Acerca del trabajo completo
LA INMUNOTERAPIA CON RUTI REDUCE EL PERIODO DE TRATAMIENTO DE LA INFECCION TUBERCULOSA LATENTE

Título original en castellano
LA INMUNOTERAPIA CON CELULAS FRAGMENTADAS DE MYCOBACTERIUM TUBERCULOSIS INCREMENTA LA EFECTIVIDAD DE LA QUIMIOTERAPIA EN UN MODELO EXPERIMENTAL DE INFECCION CRONICA TUBERCULOSA EN RATONES

Autor


Acceso a la fuente original
Vaccine
http://www.elsevier.com/locate/vaccine

El artículo se relaciona estrictamente con las especialidades de siicsalud


ua40317
-->